Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol)

Follicular lymphoma: results of multicenter study of first-line therapy with bendamustine and rituximab, risk factors for adverse events (fl-rus-2013 protocol)

Background. Follicular lymphoma (FL) is the most common type of indolent lymphomas and accounts for 20–30 % of all non-Hodgkin’s lymphomas detected. High risk of recurrence and elderly patients make it difficult to choose induction therapy for FL. The R–B course in comparison with the R–CHOP course...

Full description

Saved in:
Bibliographic Details
Main Authors: E. S. Nesterova, S. K. Kravchenko, A. M. Kovrigina, E. G. Gemdzhian, L. V. Plastinina, Ya. K. Mangasarova, F. E. Babaeva, A. E. Misyurina, O. V. Margolin, A. U. Magomedova, V. I. Vorobiev, D. S. Maryin, E. A. Baryakh, Yu. Yu. Polyakov, P. A. Zeynalova, E. M. Volodicheva, N. N. Glonina, N. V. Minaeva, G. A. Davydova, V. G. Savchenko
Format: Article
Language:Russian
Published: ABV-press 2018-10-01
Series:Онкогематология
Subjects:
follicular lymphoma
first line therapy
bendamustine
rituximab
prospective study
survival analysis
multivariate analysis
cumulative incidence
competing risks
Online Access:https://oncohematology.abvpress.ru/ongm/article/view/303
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://oncohematology.abvpress.ru/ongm/article/view/303

Similar Items